Skip to content

Avantor AVTR Cumulative Gross Losses and Impairments

Cumulative Gross Losses and Impairments at other companies

Element Solutions logo
Element SolutionsESI
NewMarket logo
NewMarketNEU
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$1.6B0.0%
Gross profit$500.7M-6.4%
Operating income$99.5M-32.5%
Net income$43.3M-32.9%
EPS (diluted)$0.06-33.3%

Balance sheet

See full
Cash & equivalents$282.2M-11.4%
Total debt$3.8B-7.1%
Total equity$5.6B-8.4%
Total assets$11.7B-5.4%

Cash flow

See full
Operating cash flow$58.7M-46.3%
CapEx$33.5M+19.6%
Free cash flow$25.2M-69.0%

Valuation

See full
Market cap$6.54B-52.0%
Enterprise value$10.07B-40.4%
P/S-1.0×

Profitability

See full
Gross margin32.1%-1.4pp
Operating margin4%-5.2pp
Net margin-9.2%-19.9pp
FCF margin6.7%-3.3pp

Returns & leverage

See full
Return on equity-10.3%-22.8pp
Debt / equity0.7×0.0×
Current ratio1.8×+0.6×

Where this comes from

Reported directly by Avantor in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairedAccumulatedImpairmentLoss.

The official record: Avantor’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avantor's cumulative gross losses and impairments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avantor's cumulative gross losses and impairments?
Avantor (AVTR) reported cumulative gross losses and impairments of $823.8M in Q4 2025.
How has Avantor's cumulative gross losses and impairments changed year-over-year?
Avantor's cumulative gross losses and impairments increased by 2023.2% year-over-year, from $38.8M to $823.8M.
What is the long-term trend for Avantor's cumulative gross losses and impairments?
Over 2 years (2023 to 2025), Avantor's cumulative gross losses and impairments has grown at a 360.8% compound annual growth rate (CAGR), from $38.8M to $823.8M.
What does cumulative gross losses and impairments mean?
This metric aggregates all unrealized losses and recognized impairment charges on investment securities that have not yet been realized through a sale. It provides a comprehensive view of the negative valuation adjustments impacting the bank's equity. It is a key indicator of the credit and market risk embedded in the bank's long-term holdings.